A Phase I Study of ARQ197 in Combination With Erlotinib in Patients With Advanced/Recurrent Non-Small-Cell Lung Cancer.

Trial Profile

A Phase I Study of ARQ197 in Combination With Erlotinib in Patients With Advanced/Recurrent Non-Small-Cell Lung Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Erlotinib (Primary) ; Tivantinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 22 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Sep 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 23 Aug 2012 Planned End Date changed from 1 Sep 2011 to 1 Feb 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top